12:00 AM
 | 
Sep 27, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DISC HSV: Phase I data; Phase II

In its 110-patient placebo controlled safety and immunogenicity trial, all 3 dose levels of CTB's vaccine were well tolerated with no serious adverse events reported in both previously infected (seropositive) patients...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >